[Federal Register Volume 75, Number 163 (Tuesday, August 24, 2010)]
[Notices]
[Pages 51984-51985]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21014]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Federal Advisory Committee; Meeting of the Uniform Formulary
Beneficiary Advisory Panel
AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of the Federal Advisory Committee Act of
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended)
the Department of Defense announces that the Uniform Formulary
Beneficiary Advisory Panel (hereafter referred to as the Panel) will
meet September 23, 2010, in Washington, DC.
DATES: The meeting will be held on September 23, 2010, from 9 a.m.-12
p.m.
A closed Administrative Work Meeting will be held from 8 a.m. to 9
a.m.
ADDRESSES: The meetings will be held at the Naval Heritage Center
Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen,
Designated Federal Officer, Uniform Formulary Beneficiary Advisory
Panel; 2450 Stanley Road, Suite 208; Ft. Sam Houston, TX 78234-6102;
Telephone: (210) 295-1271, Fax: (210) 295-2789, E-mail:
[email protected].
SUPPLEMENTARY INFORMATION:
Purpose of Meeting
The Panel will review and comment on recommendations made to the
Director, TRICARE Management Activity, by the Pharmacy and Therapeutics
Committee regarding the Uniform Formulary.
Meeting Agenda
Sign-In; Welcome and Opening Remarks; Public Citizen Comments;
Scheduled Therapeutic Class Reviews--Ophthalmic Agents (Nonsteroidal
Anti-Inflammatory, Mast Cell Stabilizers, Steroids, and
Antihistamines), Renin-Angiotensin Antihypertensives (RAAS), pertinent
utilization management issues, drugs recommended for non-formulary
placement due to non-compliance with the National Defense Authorization
Act for Fiscal Year 2008, Section 703; Panel Discussions and Vote; and
comments following each therapeutic class review.
Meeting Accessibility
Pursuant to 5 U.S.C. 552b, as amended, and Title 41, Code of
Federal Regulations (CFR), Section 102-3.140 through 102-3.165, and the
availability of space this meeting is open to the public. Seating is
limited and will be provided only to the first 220 people signing in.
All persons must sign in legibly.
Administrative Work Meeting
Prior to the public meeting the Panel will conduct an
Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss
administrative matters of the Panel. The Administrative Work Meeting
will be held at the Naval Heritage Center, 701 Pennsylvania Avenue,
NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the
Administrative Work Meeting will be closed to the public.
Written Statements
Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel at any time or in response to the stated agenda
of a planned meeting. Written statements should be submitted to the
Panel's Designated Federal Officer (DFO). The DFO's contact information
can be obtained from the General Services Administration's Federal
Advisory Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
Written statements that do not pertain to the scheduled meeting of
the Panel may be submitted at any time. However, if individual comments
pertain to a specific topic being discussed at a planned meeting, then
these statements must be submitted no later than 5 business days prior
to the meeting in question. The DFO will review all submitted written
statements and provide copies to all the committee members.
Public Comments
In addition to written statements, the Panel will set aside 1 hour
for individuals or interested groups to address the Panel. To ensure
consideration of their comments, individuals and interested groups
should submit written statements as outlined in this notice; but if
they still want to address the Panel, then they will be afforded the
opportunity to register to address the Panel. The Panel's DFO will have
a ``Sign-Up Roster'' available at the Panel meeting, for registration
on a first-come, first-served basis. Those wishing to address the Panel
will be given no more than 5 minutes to present their comments, and at
the end of the 1 hour time period no further public comments will be
accepted. Anyone who signs up to address the Panel, but is unable to do
so due to the time limitation, may submit their comments in writing;
however, they must understand that their written comments may not be
reviewed prior to the Panel's deliberation. Accordingly,
[[Page 51985]]
the Panel recommends that individuals and interested groups consider
submitting written statements instead of addressing the Panel.
Dated: August 19, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-21014 Filed 8-23-10; 8:45 am]
BILLING CODE 5001-06-P